Mai Capital Management Acadia Pharmaceuticals Inc Transaction History
Mai Capital Management
- $15.6 Billion
- Q3 2025
A detailed history of Mai Capital Management transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Mai Capital Management holds 100 shares of ACAD stock, worth $2,402. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100Holding current value
$2,402% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ACAD
# of Institutions
373Shares Held
162MCall Options Held
1.46MPut Options Held
1.09M-
Baker Bros. Advisors LP New York, NY42.9MShares$1.03 Billion7.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.2MShares$365 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$290 Million0.0% of portfolio
-
State Street Corp Boston, MA7.26MShares$174 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.14MShares$172 Million2.04% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.89B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...